Judit Borcsok

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Identification of an ERCC2 mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.

Identification of an ERCC2 mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.

Journal: bioRxiv : the preprint server for biology
Published: February 27, 2026

Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deficiency status in solid tumors.

Polymerase theta expression is correlated with proliferative capacity but not with DNA repair deficiency status in solid tumors.

Journal: NPJ precision oncology
Published: March 17, 2025

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.

The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.

Journal: The Journal of clinical investigation
Published: October 22, 2024

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.

G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.

Journal: JCI insight
Published: September 20, 2024

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.

Journal: The Journal of clinical investigation
Published: September 06, 2024

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Journal: Scientific reports
Published: August 05, 2024

Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.

Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.

Journal: NPJ precision oncology
Published: May 06, 2024

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency.

Journal: Research square
Published: April 22, 2024

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Journal: NPJ precision oncology
Published: February 27, 2024

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.

Journal: Science advances
Published: November 22, 2023

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.

Journal: NPJ precision oncology
Published: October 31, 2023

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Journal: Scientific reports
Published: August 08, 2023
Showing 1-12 of 23

Last Updated: 09/26/2026